These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
120 related articles for article (PubMed ID: 38797001)
1. Incorporation of PD-1 blockade into induction chemotherapy improved tumor response in patients with locoregionally advanced nasopharyngeal carcinoma in a retrospective patient cohort. Yao Y; Ouyang Q; Wang S; Li K; Luo Q; Qiu L; Liu F; Tan L; Li Q; Ren B; Long P; Ye J; Zhong X Oral Oncol; 2024 Jul; 154():106867. PubMed ID: 38797001 [TBL] [Abstract][Full Text] [Related]
2. The efficacy and safety of adding PD-1 blockade to induction chemotherapy and concurrent chemoradiotherapy (IC-CCRT) for locoregionally advanced nasopharyngeal carcinoma: an observational, propensity score-matched analysis. Jin YN; Qiang MY; Wang Y; Lin YJ; Jiang RW; Cao WW; Zhang WJ; Wang SY; Zhang HY; Yao JJ Cancer Immunol Immunother; 2024 May; 73(7):125. PubMed ID: 38733402 [TBL] [Abstract][Full Text] [Related]
3. The short-term efficacy and safety of induction chemotherapy combined with PD-1 inhibitor or anti-EGFR in locoregionally advanced nasopharyngeal carcinoma. Xiang X; Chen P; Lan F; Ma L; Jin J; Zhang Y Front Oncol; 2023; 13():1110281. PubMed ID: 37152052 [TBL] [Abstract][Full Text] [Related]
4. Additional PD-1 inhibitor improves complete response to induction chemotherapy in locally advanced nasopharyngeal carcinoma. Yu YF; Lu GZ; Wang RJ; Song YK; Wu SG Front Immunol; 2024; 15():1415246. PubMed ID: 38911859 [TBL] [Abstract][Full Text] [Related]
5. Analysis of the clinical efficacy and safety of anti-PD-1 immune checkpoint inhibitors in locally advanced nasopharyngeal cancer. Shi S; Li B; Zhou P; Chen L; Li H; Wang Y; Deng X; Dang Q; Wu J; Zha B; Li P; Zheng Y; Yang D Cancer Med; 2024 Jul; 13(14):e7359. PubMed ID: 39032129 [TBL] [Abstract][Full Text] [Related]
6. Optimal cumulative cisplatin dose in nasopharyngeal carcinoma patients based on induction chemotherapy response. Liu SL; Sun XS; Yan JJ; Chen QY; Lin HX; Wen YF; Guo SS; Liu LT; Xie HJ; Tang QN; Liang YJ; Li XY; Lin C; Du YY; Yang ZC; Xiao BB; Yang JH; Tang LQ; Guo L; Mai HQ Radiother Oncol; 2019 Aug; 137():83-94. PubMed ID: 31078941 [TBL] [Abstract][Full Text] [Related]
7. Determination of optimum number of cycles of induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: a single-center retrospective study. Ahmed AO; Wang J; Wu Q; Zhong Y Eur Arch Otorhinolaryngol; 2023 Apr; 280(4):1999-2006. PubMed ID: 36629931 [TBL] [Abstract][Full Text] [Related]
8. Induction chemotherapy plus IMRT alone versus induction chemotherapy plus IMRT-based concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study. Wei Z; Zhang Z; Luo J; Li N; Peng X J Cancer Res Clin Oncol; 2019 Jul; 145(7):1857-1864. PubMed ID: 31062162 [TBL] [Abstract][Full Text] [Related]
9. Induction chemotherapy followed by concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: long-term results of a phase III multicentre randomised controlled trial. Yang Q; Cao SM; Guo L; Hua YJ; Huang PY; Zhang XL; Lin M; You R; Zou X; Liu YP; Xie YL; Wang ZQ; Mai HQ; Chen QY; Tang LQ; Mo HY; Cao KJ; Qian CN; Zhao C; Xiang YQ; Zhang XP; Lin ZX; Li WX; Liu Q; Li JB; Ling L; Guo X; Hong MH; Chen MY Eur J Cancer; 2019 Sep; 119():87-96. PubMed ID: 31425966 [TBL] [Abstract][Full Text] [Related]
10. Sequential induction chemotherapy plus intensity-modulated radiotherapy versus concurrent chemoradiotherapy in locoregionally advanced nasopharyngeal carcinoma: the three-year report of a phase II, single center, randomized, non-inferiority trial. Yang Z; Cai Z; Cai Q; Hong Y; Zhang C; Huang K; Lin Z; Li M Cancer Med; 2021 Jun; 10(12):3886-3895. PubMed ID: 33955190 [TBL] [Abstract][Full Text] [Related]
11. Matched analysis of induction chemotherapy plus chemoradiotherapy versus induction chemotherapy plus radiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a multicenter study. Zhang B; Hu Y; Xiong RH; Pan YF; Xu QL; Kong XY; Cai R; Chen QQ; Tang HY; Jiang W Oncotarget; 2017 Feb; 8(8):14078-14088. PubMed ID: 27845907 [TBL] [Abstract][Full Text] [Related]
12. Induction Chemotherapy Plus Concurrent Chemoradiotherapy Versus Concurrent Chemoradiotherapy Alone in Locoregionally Advanced Nasopharyngeal Carcinoma in Children and Adolescents: A Matched Cohort Analysis. Li Y; Tang LQ; Liu LT; Guo SS; Liang YJ; Sun XS; Tang QN; Bei JX; Tan J; Chen S; Ma J; Zhao C; Chen QY; Mai HQ Cancer Res Treat; 2018 Oct; 50(4):1304-1315. PubMed ID: 29334605 [TBL] [Abstract][Full Text] [Related]
13. Induction chemotherapy plus concurrent chemoradiotherapy versus induction chemotherapy plus volumetric modulated arc therapy alone in the treatment of stage II-IVB nasopharyngeal carcinoma patients: a retrospective controlled study. Liu L; Fei Z; Chen M; Zhao L; Su H; Gu D; Lin B; Cai X; Lu L; Gao M; Ye X; Jin X; Xie C Radiat Oncol; 2018 Aug; 13(1):148. PubMed ID: 30103765 [TBL] [Abstract][Full Text] [Related]
14. Individualized number of induction chemotherapy cycles for locoregionally advanced nasopharyngeal carcinoma patients based on early tumor response. Jiang YT; Chen KH; Liang ZG; Yang J; Qu S; Li L; Zhu XD Cancer Med; 2023 Feb; 12(4):4010-4022. PubMed ID: 36127746 [TBL] [Abstract][Full Text] [Related]
15. Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area. Fangzheng W; Chuner J; Haiyan Q; Quanquan S; Zhimin Y; Tongxin L; Jiping L; Peng W; Kaiyuan S; Zhenfu F; Yangming J Medicine (Baltimore); 2019 Dec; 98(51):e18484. PubMed ID: 31861031 [TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of docetaxel, cisplatin and fluorouracil (TPF)-based induction chemotherapy followed by concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a meta-analysis. Zhou R; Zhu J; Chen X; Liu Y; Wang Y; Zhang T Clin Transl Oncol; 2020 Mar; 22(3):429-439. PubMed ID: 31165410 [TBL] [Abstract][Full Text] [Related]
17. The comparison of prognostic value of tumour volumetric regression ratio and RECIST 1.1 criteria after induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Zeng YY; Xiang ZZ; He T; Liu F; Shao BF; Yan RN; Ma JC; Wang XR; Liu L Oral Oncol; 2020 Dec; 111():104924. PubMed ID: 32736209 [TBL] [Abstract][Full Text] [Related]
18. Efficacy of adjuvant chemotherapy/maintenance chemotherapy after induction chemotherapy and concurrent chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma: Experiences of two centers. Tao HY; He F; Shi QY; Liu R; Wang ZL; Du KP; Li JF; Liu H; Lu ZQ; Zhang JJ; Bai YH Cancer Med; 2023 Mar; 12(6):6811-6824. PubMed ID: 36420689 [TBL] [Abstract][Full Text] [Related]
19. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis. Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487 [TBL] [Abstract][Full Text] [Related]
20. Optimizing the induction chemotherapy regimen for patients with locoregionally advanced nasopharyngeal Carcinoma: A big-data intelligence platform-based analysis. Peng H; Tang LL; Chen BB; Chen L; Li WF; Mao YP; Liu X; Zhang Y; Liu LZ; Tian L; Guo Y; Sun Y; Ma J Oral Oncol; 2018 Apr; 79():40-46. PubMed ID: 29598949 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]